Skip to main content
Top
Published in: Internal and Emergency Medicine 2/2020

01-03-2020 | Ulcerative Colitis | IM - ORIGINAL

Defective spleen function in autoimmune gastrointestinal disorders

Authors: Paolo Giuffrida, Nicola Aronico, Matteo Rosselli, Marco Vincenzo Lenti, Sara Cococcia, Davide Roccarina, Francesca Saffioti, Mariangela Delliponti, Douglas Thorburn, Emanuela Miceli, Gino Roberto Corazza, Massimo Pinzani, Antonio Di Sabatino

Published in: Internal and Emergency Medicine | Issue 2/2020

Login to get access

Abstract

Defective spleen function increases susceptibility to bacterial infections which can be prevented by vaccine prophylaxis. Splenic hypofunction can be found in a number of autoimmune disorders; however, no data are available regarding autoimmune atrophic gastritis (AAG), autoimmune enteropathy (AIE) and autoimmune liver disease (AILD). Peripheral blood samples from patients with AAG (n = 40), AIE (n = 3) and AILD (n = 40) were collected. Patients affected by autoimmune disorders already known to be associated with splenic hypofunction, i.e. coeliac disease (CD) and ulcerative colitis (UC), were included as disease controls, while splenectomised patients and healthy subjects were evaluated as positive and negative controls, respectively. Counting of erythrocytes with membrane abnormalities, i.e. pitted red cells, was used as an indicator of spleen function (normal upper limit 4%). Defective splenic function was observed in 22 of the 40 patients with AAG (55.0%), in two of the three patients with AIE (66.6%) and in 35 of the 40 patients with AILD (87.5%). As expected, in untreated CD, refractory CD and UC there was a high prevalence of hyposplenism (43.7%, 88.2% and 54.4%, respectively). Due to the high prevalence of splenic hypofunction, patients with AAG, AILD and AIE should undergo pitted red cell evaluation and, if hyposplenic, they should be candidate to vaccine prophylaxis against encapsulated bacteria.
Literature
1.
go back to reference Di Sabatino A, Carsetti R, Corazza GR (2011) Post-splenectomy and hyposplenic states. Lancet 378:86–97CrossRef Di Sabatino A, Carsetti R, Corazza GR (2011) Post-splenectomy and hyposplenic states. Lancet 378:86–97CrossRef
2.
go back to reference Corazza GR, Zoli G, Di Sabatino A et al (1999) A reassessment of splenic hypofunction in celiac disease. Am J Gastroenterol 94:391–397CrossRef Corazza GR, Zoli G, Di Sabatino A et al (1999) A reassessment of splenic hypofunction in celiac disease. Am J Gastroenterol 94:391–397CrossRef
3.
go back to reference Di Sabatino A, Brunetti L, Carnevale Maffè G et al (2013) Is it worth investigating splenic function in patients with celiac disease? World J Gastroenterol 19:2313–2318CrossRef Di Sabatino A, Brunetti L, Carnevale Maffè G et al (2013) Is it worth investigating splenic function in patients with celiac disease? World J Gastroenterol 19:2313–2318CrossRef
4.
go back to reference Di Sabatino A, Rosado MM, Ciccocioppo R et al (2005) Depletion of immunoglobulin M memory B cells is associated with splenic hypofunction in inflammatory bowel disease. Am J Gastroenterol 100:1788–1795CrossRef Di Sabatino A, Rosado MM, Ciccocioppo R et al (2005) Depletion of immunoglobulin M memory B cells is associated with splenic hypofunction in inflammatory bowel disease. Am J Gastroenterol 100:1788–1795CrossRef
5.
go back to reference Di Sabatino A, Aronico N, Giuffrida P et al (2018) Association between defective spleen function and primary eosinophilic gastrointestinal disorders. J Allergy Clin Immunol Pract 6:1056–1058CrossRef Di Sabatino A, Aronico N, Giuffrida P et al (2018) Association between defective spleen function and primary eosinophilic gastrointestinal disorders. J Allergy Clin Immunol Pract 6:1056–1058CrossRef
6.
go back to reference Di Sabatino A, Rosado MM, Cazzola P et al (2006) Splenic hypofunction and the spectrum of autoimmune and malignant complications in celiac disease. Clin Gastroenterol Hepatol 4:179–186CrossRef Di Sabatino A, Rosado MM, Cazzola P et al (2006) Splenic hypofunction and the spectrum of autoimmune and malignant complications in celiac disease. Clin Gastroenterol Hepatol 4:179–186CrossRef
7.
go back to reference Simons M, Scott-Sheldon LAJ, Risech-Neyman Y et al (2018) Celiac disease and increased risk of pneumococcal infection: a systematic review and meta-analysis. Am J Med 131:83–89CrossRef Simons M, Scott-Sheldon LAJ, Risech-Neyman Y et al (2018) Celiac disease and increased risk of pneumococcal infection: a systematic review and meta-analysis. Am J Med 131:83–89CrossRef
8.
go back to reference Emilsson L, Lebwohl B, Green PH et al (2018) Mucosal healing and the risk of serious infections in patients with celiac disease. United Eur Gastroenterol J 6:55–62CrossRef Emilsson L, Lebwohl B, Green PH et al (2018) Mucosal healing and the risk of serious infections in patients with celiac disease. United Eur Gastroenterol J 6:55–62CrossRef
9.
go back to reference Kruetzmann S, Rosado MM, Weber H et al (2003) Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med 197:939–945CrossRef Kruetzmann S, Rosado MM, Weber H et al (2003) Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med 197:939–945CrossRef
10.
go back to reference Di Sabatino A, Rosado MM, Cazzola P et al (2008) Splenic function and IgM-memory B cells in Crohn’s disease patients treated with infliximab. Inflamm Bowel Dis 14:591–596CrossRef Di Sabatino A, Rosado MM, Cazzola P et al (2008) Splenic function and IgM-memory B cells in Crohn’s disease patients treated with infliximab. Inflamm Bowel Dis 14:591–596CrossRef
11.
go back to reference Dixon MF, Genta RM, Yardley JH et al (1996) Classification and grading of gastritis. The updated Sydney system. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 20:1161–1181CrossRef Dixon MF, Genta RM, Yardley JH et al (1996) Classification and grading of gastritis. The updated Sydney system. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 20:1161–1181CrossRef
12.
go back to reference Di Sabatino A, Biagi F, Lenzi M et al (2017) Clinical usefulness of serum antibodies as biomarkers of gastrointestinal and liver diseases. Dig Liver Dis 49:947–956CrossRef Di Sabatino A, Biagi F, Lenzi M et al (2017) Clinical usefulness of serum antibodies as biomarkers of gastrointestinal and liver diseases. Dig Liver Dis 49:947–956CrossRef
13.
go back to reference European Association for the Study of the Liver (2015) EASL Clinical Practice Guidelines: autoimmune hepatitis. J Hepatol 63:971–1004CrossRef European Association for the Study of the Liver (2015) EASL Clinical Practice Guidelines: autoimmune hepatitis. J Hepatol 63:971–1004CrossRef
14.
go back to reference European Association for the Study of the Liver (2017) EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 67:145–172CrossRef European Association for the Study of the Liver (2017) EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 67:145–172CrossRef
15.
go back to reference European Association for the Study of the Liver (2009) EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 51:237–267CrossRef European Association for the Study of the Liver (2009) EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 51:237–267CrossRef
16.
17.
go back to reference Rubio-Tapia A, Murray JA (2010) Classification and management of refractory coeliac disease. Gut 59:547–557CrossRef Rubio-Tapia A, Murray JA (2010) Classification and management of refractory coeliac disease. Gut 59:547–557CrossRef
18.
go back to reference Magro F, Gionchetti P, Eliakim R et al (2017) Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis 11:649–670CrossRef Magro F, Gionchetti P, Eliakim R et al (2017) Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis 11:649–670CrossRef
19.
go back to reference Rachmilewitz D (1989) Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 298:82–86CrossRef Rachmilewitz D (1989) Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 298:82–86CrossRef
20.
go back to reference Markus HS, Muller AF, Toghill PJ (1993) Splenic function, assessed by quantification of erythrocyte membrane pits, is normal in chronic active hepatitis and primary biliary cirrhosis. J Hepatol 18:106–111CrossRef Markus HS, Muller AF, Toghill PJ (1993) Splenic function, assessed by quantification of erythrocyte membrane pits, is normal in chronic active hepatitis and primary biliary cirrhosis. J Hepatol 18:106–111CrossRef
21.
go back to reference Trevisani F, Castelli E, Foschi FG et al (2002) Impaired tuftsin activity in cirrhosis: relationship with splenic function and clinical outcome. Gut 50:707–712CrossRef Trevisani F, Castelli E, Foschi FG et al (2002) Impaired tuftsin activity in cirrhosis: relationship with splenic function and clinical outcome. Gut 50:707–712CrossRef
22.
go back to reference Carsetti R, Rosado MM, Wardemann H (2004) Peripheral development of B cells in mouse and man. Immunol Rev 197:179–191CrossRef Carsetti R, Rosado MM, Wardemann H (2004) Peripheral development of B cells in mouse and man. Immunol Rev 197:179–191CrossRef
23.
go back to reference Arnott A, Jones P, Franklin LJ et al (2018) A registry for patients with asplenia/hyposplenism reduces the risk of infections with encapsulated organisms. Clin Infect Dis 67:557–561CrossRef Arnott A, Jones P, Franklin LJ et al (2018) A registry for patients with asplenia/hyposplenism reduces the risk of infections with encapsulated organisms. Clin Infect Dis 67:557–561CrossRef
24.
go back to reference Di Sabatino A, Lenti MV, Corazza GR (2018) Spleen registry: still a chimera. Clin Infect Dis 67:562–563CrossRef Di Sabatino A, Lenti MV, Corazza GR (2018) Spleen registry: still a chimera. Clin Infect Dis 67:562–563CrossRef
Metadata
Title
Defective spleen function in autoimmune gastrointestinal disorders
Authors
Paolo Giuffrida
Nicola Aronico
Matteo Rosselli
Marco Vincenzo Lenti
Sara Cococcia
Davide Roccarina
Francesca Saffioti
Mariangela Delliponti
Douglas Thorburn
Emanuela Miceli
Gino Roberto Corazza
Massimo Pinzani
Antonio Di Sabatino
Publication date
01-03-2020
Publisher
Springer International Publishing
Published in
Internal and Emergency Medicine / Issue 2/2020
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-019-02129-w

Other articles of this Issue 2/2020

Internal and Emergency Medicine 2/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine